Marc Goodman
Stock Analyst at Leerink Partners
(2.91)
# 1,541
Out of 4,786 analysts
98
Total ratings
55.41%
Success rate
26.34%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $116.63 | +28.61% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.27 | +270.37% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $24.04 | +149.58% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $25.71 | +24.47% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $3.54 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $66.22 | -62.25% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $13.60 | +267.78% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $12.03 | +66.25% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $110.60 | +3.98% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $136.84 | +126.54% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $7.83 | +53.26% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $33.55 | +37.11% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $16.61 | +26.43% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $124.15 | +69.15% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $7.95 | +403.14% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.87 | +434.76% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $33.02 | -18.23% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $70 | $131.92 | -46.94% | 3 | Apr 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.75 | +160.87% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $366.54 | -26.34% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $209.52 | -54.18% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $60.99 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $89.76 | -25.36% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $28.04 | +249.50% | 7 | Oct 5, 2017 |
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $116.63
Upside: +28.61%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.27
Upside: +270.37%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $24.04
Upside: +149.58%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $25.71
Upside: +24.47%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.54
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $66.22
Upside: -62.25%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $13.60
Upside: +267.78%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $12.03
Upside: +66.25%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $110.60
Upside: +3.98%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $136.84
Upside: +126.54%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $7.83
Upside: +53.26%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $33.55
Upside: +37.11%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $16.61
Upside: +26.43%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $124.15
Upside: +69.15%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $7.95
Upside: +403.14%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.87
Upside: +434.76%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $33.02
Upside: -18.23%
Apr 21, 2022
Maintains: Outperform
Price Target: $65 → $70
Current: $131.92
Upside: -46.94%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.75
Upside: +160.87%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $366.54
Upside: -26.34%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $209.52
Upside: -54.18%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $60.99
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $89.76
Upside: -25.36%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $28.04
Upside: +249.50%